- Company
- SK Group's Pharma companies make successive success
- by Lee, Seok-Jun Jul 30, 2021 05:48am
- SK Group’s pharmaceutical companies have successively succeeded in raising large-scale funds. The analysis is that being able to invest in independent corporations differentiated by business characteristics attracted market investment. SK Group’s pharmaceutical companies, which all use the SK name, are operated in different areas by SK or S
- Company
- Emgality and Ajovy were also approved
- by Kim, Jin-Gu Jul 30, 2021 05:47am
- Following Lilly's Emgality (Galcanezumab), Teva's Ajovy (Fremanezumab) were released in Korea as a new medicine for migraine prevention. Attention is focusing on whether CGRP (calcitonin gene-related peptide) drugs, which have entered the domestic migraine treatment market without suitable treatments, will become popular. Aimovig is not
- Company
- Chong Kun Dang applied for Lucentis biosimilar
- by Chon, Seung-Hyun Jul 30, 2021 05:47am
- Chung Kun Dang announced on the 28th that it has applied to the MFDS for permission for the item of the macular denaturation drug CKD-701. CKD-701(Ranibizumab) is a biosimilar product from Lucentis. Lucentis, sold by Roche and Novartis, is a drug used to treat ophthalmic diseases such as macular degenerative diabetes and macular edema. Lucent
- Company
- Sales of Takeda’s drugs 'acquired by Celltrion' drop 9%
- by Kim, Jin-Gu Jul 29, 2021 05:52am
- Prescriptions of chronic disease drugs that Celltrion acquired from Takeda Pharmaceuticals dropped 9% year-on-year in the first half of this year. Sales of most of the products were already decreasing in the domestic market at the time of Celltrion’s acquisition, and the prolonged COVID-19 crisis contracted the prescription market and fu
- Company
- Anterogen to finish analysis for its diabetic foot ulcer Tx
- by Lee, Seok-Jun Jul 29, 2021 05:52am
- Anterogen will be completing data cleaning on its Phase III trial (DFU-301) that was conducted in Korea at the end of August at the earliest. If the analysis goes as planned, the company plans to seek marketing authorization for its product after completing the analysis. Anterogen announced these plans at the IR meeting on the 28th. Acc
- Company
- Viatris and Organon's sales are sluggish
- by Kim, Jin-Gu Jul 29, 2021 05:52am
- Viatris, which was officially launched at the end of last year, had low sales in the first half of this year. The amount of outpatient prescriptions for major products decreased by 8% compared to the first half of last year before independence from the Pfizer. Organon, separated from MSD, has a similar situation. Prescription performanc
- Company
- Daewoong's COVID drug PO is effective for patients over 50
- by Lee, Seok-Jun Jul 29, 2021 05:52am
- Daewoong's COVID drug PO has cut the time to improve respiratory symptoms of patients aged 50 or older by half compared to placebo. Daewoong announced the results of Topline in clinical 2b of Coviblock (Camostat), which is being developed as a treatment for COVID-19. Clinical trials were conducted in 24 institutions from February to July t
- Company
- Nitrosamines test plan must also be submitted
- by Chon, Seung-Hyun Jul 28, 2021 05:56am
- The government is further strengthening pharmaceutical companies' self-inspection of impurities. Plans should be submitted by the end of this month to test for possible Nitrosamine impurities.. The submission of test results is due in May next year. According to the industry on the 27th, the MFDS recently asked pharmaceutical companies to
- Company
- Samsung Biologics record-high earnings of ₩166.8 in Q2
- by An, Kyung-Jin Jul 28, 2021 05:55am
- Samsung Biologics posted positive records despite the prolonged COVID-19 crisis. The increased utilization rate of the company’s third plant and new product orders drove the company to record the highest-ever sales and operating profit this quarter. On the 27th, Samsung Biologics announced that its operating profit in Q2 this year was 16
- Company
- Domestic DDP-4 inhibitors fare better amid sales decline
- by Kim, Jin-Gu Jul 28, 2021 05:55am
- Prescription of DPP-4 inhibitors, which used to drive the diabetes treatment market, are on the decline. In just a single year, the market size of DPP-4 inhibitors decreased 4%, and this is the third consecutive quarter the market saw a decline since Q4 last year. Also, multinational companies and domestic companies have seen opposite results
